Contents
07 February 2018
Vol 10, Issue 427
Vol 10, Issue 427
Research Articles
- Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance
A transgelin-2 agonist relaxes airway smooth muscle cells and provides therapeutic advantages for asthma.
- Targeting p53-dependent stem cell loss for intestinal chemoprotection
Targeting of p53- and PUMA-dependent apoptosis protects intestinal stem cells, but not cancer cells, against chemotherapy.
- Targeting mitochondrial responses to intra-articular fracture to prevent posttraumatic osteoarthritis
Inhibiting mitochondrial oxidant production after surgical fixation of an intra-articular fracture prevents osteoarthritis in a porcine model.
- PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia
PP2A inhibitors and BCR-ABL inhibitors synergize to kill drug-insensitive leukemia cells.
- Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism
The histone deacetylase inhibitor ITF2357 (givinostat) prevents diastolic dysfunction by enhancing cardiac myofibril relaxation.
Editors' Choice
- Deadly role of chromosomal instability in metastasis
Chromosomal instability produces cytosolic micronuclei that rupture and activate a viral response pathway, driving metastasis.
- Endothelial cells: The heart attack of the clones
Neovascularization induced by acute myocardial infarction is mediated by clonal expansion of mature endothelial cells, which is triggered by VEGFR-2 signaling.
- No one is naïve: Young infant’s immunity can dodge Darwinian selection
Unlike adults, young infant antibody responses against respiratory syncytial virus are biased toward limited antigenic sites, suggesting a blueprint for future infant and age-specific vaccines.
About The Cover
ONLINE COVER Countering Constriction in Asthma. Asthma patients can be refractory to current therapies, so alternative approaches are needed. Yin et al. demonstrated that TSG12, a transgelin-2 agonist, relaxed airways in preclinical asthma mouse models. Shown here is the reduced traction force of human airway smooth muscle cells after treatment with TSG12 (second and fourth images), compared to untreated control cells (first and third images). This agonist was more potent than currently used β2-agonists and could help patients with asthma breathe more easily. [CREDIT: YIN ET AL./SCIENCE TRANSLATIONAL MEDICINE]
